To read the full story, subscribe or sign in.

Genexine, EPD Biotherapeutics to merge for new protein degraders

July 9, 2024

Seoul, South Korea-based Genexine Co. Ltd. plans to merge with privately held EPD Biotherapeutics Co. Ltd. by October 2024 to build a pipeline of novel targeted protein degradation therapeutics with EPD Bio’s BioPROTAC platform technology.

BioWorld Asia Deals and M&A Cancer Protein Asia-Pacific

Today's news in brief

BioWorld

BioWorld briefs for April 3, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 2, 2025.

Medtronic, Recor commence hostilities over RDN patents

BioWorld MedTech

The renal denervation patent wars are now in full swing, with Medtronic plc and Recor Medical LLC landing the first blow in this chapter of the med tech patent...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...

Illustration of Microglia cells (red) in Alzheimer´s disease

ADPD 2025: Emerging strategies fueling Alzheimer’s disease research

BioWorld Science

During the first oral sessions on Translational Drug Discovery at the 19th Alzheimer’s & Parkinson’s Diseases (ADPD) Conference, Beka Solomon from Tel Aviv...